FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:2657 December 16, 2004 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Spragg, R. G. PubMed Citation

To the Editor: The phase 3 studies on the effect of recombinant surfactant protein C in the acute respiratory distress syndrome, reported by Spragg et al. (Aug. 26 issue),¹ address an important question. I would be interested in an explanation (biologic or otherwise) for the observed improvement in oxygenation in the first 24 hours in the group receiving active treatment, as compared with the control group, but an observed (albeit nonstatistical) trend toward a reduction in ventilator-free days (3.5 vs. 6 days) and a lower survival rate at 28 days (68 vs. 75 percent) in the North American Study. Could . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.